Pharmacokinetic interactions with calcium channel antagonists (Part II).
Since calcium channel antagonists are a diverse class of drugs frequently administered in combination with other agents, the potential for clinically significant pharmacokinetic drug interactions exists. These interactions occur most frequently via altered hepatic blood flow and impaired hepatic enzyme activity. Part I of the article, which appeared in the previous issue of the Journal, dealt with interactions between calcium antagonists and marker compounds, theophylline, midazolam, lithium, doxorubicin, oral hypoglycaemics and cardiac drugs. Part II examines interactions with cyclosporin, anaesthetics, carbamazepine and cardiovascular agents.
Schlanz
K D
KD
Division of Clinical and Hospital Pharmacy, College of Pharmacy, University of Cincinnati Medical Center, Ohio.
Myre
S A
SA
Bottorff
M B
MB
D000777:Anesthetics; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics*; D002220:Carbamazepine / Q000494:pharmacology; D002317:Cardiovascular Agents / Q000494:pharmacology; D003524:Cyclosporins / Q000494:pharmacology; D004347:Drug Interactions; D006801:Humans
D000777:Anesthetics; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D003524:Cyclosporins; D002220:Carbamazepine